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Abstract
Background: Dose-dependent processes are common within biological systems and include
phenotypic changes following exposures to both endogenous and xenobiotic molecules. The use
of microarray technology to explore the molecular signals that underlie these dose-dependent
processes has become increasingly common; however, the number of software tools for
quantitatively analyzing and interpreting dose-response microarray data has been limited.
Results: We have developed BMDExpress, a Java application that combines traditional benchmark
dose methods with gene ontology classification in the analysis of dose-response data from
microarray experiments. The software application is designed to perform a stepwise analysis
beginning with a one-way analysis of variance to identify the subset of genes that demonstrate
significant dose-response behavior. The second step of the analysis involves fitting the gene
expression data to a selection of standard statistical models (linear, 2° polynomial, 3° polynomial,
and power models) and selecting the model that best describes the data with the least amount of
complexity. The model is then used to estimate the benchmark dose at which the expression of
the gene significantly deviates from that observed in control animals. Finally, the software
application summarizes the statistical modeling results by matching each gene to its corresponding
gene ontology categories and calculating summary values that characterize the dose-dependent
behavior for each biological process and molecular function. As a result, the summary values
represent the dose levels at which genes in the corresponding cellular process show transcriptional
changes.
Conclusion: The application of microarray technology together with the BMDExpress software
tool represents a useful combination in characterizing dose-dependent transcriptional changes in
biological systems. The software allows users to efficiently analyze large dose-response microarray
studies and identify reference doses at which particular cellular processes are altered. The software
is freely available at http://sourceforge.net/projects/bmdexpress/ and is distributed under the MIT
Public License.
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Background
The endogenous control and external perturbation of bio-
logical processes are inherently dose-dependent. Exam-
ples include developmental events that require gradients
of growth factor concentrations [1], zonation in the liver
due to differences in oxygen and nutrient concentration
[2], the pharmacological inhibition of key proteins in dis-
ease [3], and the toxic effects of environmental chemicals
[4]. Without a proper understanding of the dose-response
characteristics, the molecular mechanisms underlying the
regulation or perturbation of these biological processes
would remain unknown.
Microarray technology has been broadly accepted as an
efficient and reproducible way to explore the gene expres-
sion changes involved in the regulation of biological proc-
esses. The ability to survey thousands of genes allows a
comprehensive assessment of the transcriptional changes
involved in specific cellular events. Bioinformatic meth-
ods have been developed to interpret these changes by
applying standardized functional annotations to each
gene and identifying whether certain biological processes
or molecular functions are over- or under-represented [5-
10]. This approach has been referred to as a gene ontology
(GO) enrichment analysis and allows large lists of tran-
scriptional alterations to be distilled down into changes in
cellular processes such as the immune response, DNA
repair, apoptosis, etc.
To quantitatively assess the dose-response behavior of
endogenous molecules and environmental chemicals,
benchmark dose (BMD) methods have been employed to
estimate reference doses [11-13]. In the BMD method,
dose-response data for the biological effect is fit with a sta-
tistical model and a BMD is identified that results in a
defined level of response over that observed in control
populations. The BMD method has been used extensively
by regulatory agencies to set standards for human health
effects [14,15].
A method for integration of BMD calculations with GO
classification analysis in the examination of microarray
dose-response data has recently been developed [16]. The
combination of microarray technology with these analysis
methods results in a unique bioinformatic tool that pro-
vides both a comprehensive survey of transcriptional
changes together with dose estimates at which different
cellular processes are altered based on a defined increase
in response. In this application note, we describe the
development and availability of a user-friendly software
tool that integrates these standard methods in the analysis
of microarray dose-response data.
Implementation
BMDExpress was written in the Java programming lan-
guage with a Swing graphical user interface. The applica-
tion requires a Java Runtime Environment of 1.6.0 or
newer. Model fitting to the dose-response data is per-
formed using a dynamic link library (DLL) written in C
and FORTRAN that are called using a Java Native Inter-
face. The DLL was written using source code modified
from the BMDS software application developed by the
U.S. Environmental Protection Agency [17]. In mapping
the Affymetrix probe identifiers to corresponding GO cat-
egories, the software application queries a client-accessi-
ble MySQL database that resides at The Hamner Institutes.
The database is constructed using annotations provided
by NetAffx [18] and the Gene Ontology Consortium [19].
The database is updated weekly to ensure the annotations
are current. At the present time, only Affymetrix microar-
rays are supported by BMDExpress and include the fol-
lowing: Human (HG_Focus, HG_U133A, HG-U133A_2,
and HG-U133_Plus_2); Mouse (MG_U74A,
MG_U74Av2, MOE430A, MOE430B, Mouse430A_2, and
Mouse430_2); Rat (RAE230A, RAE230B, Rat230_2, and
RG_U34A); Drosophila (DrosGenome1 and
Drosophila_2); and Zebrafish (Zebrafish Genome).
Results and Discussion
The BMDExpress software is designed to perform a step-
wise analysis on dose-response microarray data that com-
bines standard BMD methods with GO classification
analysis. The program has a series of interfaces that guide
the user through the analysis process.
Data Import
The first step in using BMDExpress is to load the gene
expression data from a data file (Fig. 1A). The data file
must be in tab-delimited format with plain text. Each col-
umn in the data matrix should be the gene expression val-
ues for an individual sample and the first row should
include the dose at which that sample was treated. If the
data has an extra row of column headers, the program
provides an option for removing them. An example data
file is included in the software installation
(Finalexpress100.txt).
One-Way ANOVA
The number of probe sets on a standard Affymetrix micro-
array is relatively large and in the typical experiment, most
probe sets are not significantly altered by the experimental
treatment. As a result, an initial probe set selection process
is recommended to reduce both the computational
requirements and the variability in the final analysis by
selecting probe sets that show significant dose-response
behavior. The probe set selection process consists of a
one-way analysis of variance (ANOVA) together with a
false discovery rate correction for multiple comparisonsBMC Genomics 2007, 8:387 http://www.biomedcentral.com/1471-2164/8/387
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[20] (Fig. 1B). The user is allowed to input a cutoff based
on the adjusted p-value and may choose whether to filter
out the various control genes (e.g., BioB, BioC, etc.)
present on an Affymetrix array. The output of the one-way
ANOVA lists the probe set identifier, the associated
degrees of freedom, the F-value, the p-value, and the
adjusted p-value. The user can export the list to a tab-
delimited file by right-clicking on the corresponding node
in the data tree within the left-hand window.
Benchmark Dose Analyses
The generic definition of a BMD is the dose or concentra-
tion of a substance that corresponds to a specified level of
response above or below that observed in a control or
background population. The specified level of response
within this definition is referred to as the benchmark
response (BMR) and a statistical lower confidence bound
on the BMD (BMDL) has been typically used by regula-
tory agencies to set safe levels of exposure. In BMDEx-
Screen shots of BMDExpress software application Figure 1
Screen shots of BMDExpress software application. The software uses standard drop-down windows for user interaction and 
the left-hand side of the main window contains a tree structure that outlines progress through the analysis process. (A) Inter-
face for data import. The data is previewed in table format and if the input data has column headers, the user is provided the 
option to remove headers within the software interface. (B) Interface for pre-filtering data using a one-way ANOVA. The user 
is allowed to input an adjusted p-cutoff and select whether to filter out the various control genes (e.g., BioB, BioC, etc.) 
present on an Affymetrix array. (C) Interface for benchmark dose analysis. The user is allowed to select the type of statistical 
models and parameters used in the analysis and provided options on the process of selecting the best model. (D) Interface for 
gene ontology analysis. The BMD values from the previous step in the analysis process are used as input for the gene ontology 
analysis. The organism is automatically detected by the software based on the probe set identifiers. The user is allowed to 
select the class of gene ontology categories for the analysis with either biological process, molecular function, cell component, 
or universal (all three) as options.BMC Genomics 2007, 8:387 http://www.biomedcentral.com/1471-2164/8/387
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press, the identification of the BMD involves fitting the
gene expression data to a selection of statistical models
(linear, 2° polynomial, 3° polynomial, and power mod-
els) and selecting the model that best describes the data
with the least amount of complexity (Fig. 1C). The user is
allowed to select which statistical models they would like
to fit to the data. By default, the power model and the
three polynomial models are selected. However, the user
can select a single model or any combination of two or
more models. The user should note that depending on the
number of doses in the study, the 3° polynomial may not
be appropriate. In addition to model selection, the user is
allowed to modify several critical parameters associated
with the BMD analyses including the maximum number
of iterations, the BMR, and the confidence level for calcu-
lation of the BMDL. The maximum number of iterations
is a convergence criteria for the model fitting. The BMR is
the number of standard deviations at which the BMD is
defined. As a default, a BMR of 1.349 is provided. To
derive this value, a normal distribution was assumed for
control animals and it was assumed, a priori, that the
changes in expression could occur in either tail, with a 1%
chance of that occurring in the absence of exposure (0.5%
in each tail). A BMR of 1.349 is the amount required to
shift the mean response of the control distribution such
that the treated distribution contains 11% in a single tail,
i.e., a 10% increase over the assumed background rate of
response. The 10% value for the shift in the tail area of the
distribution is standard for BMD analysis [16,21]. The
confidence level is the statistical lower confidence limit
applied to BMD estimated by the model. The resultant
lower bound on the BMD is the BMDL and is a conserva-
tive estimate of the dose at which the particular gene is
altered.
In processing the model output, the user is allowed to
choose the method for selecting which model best
describes the data with the least amount of complexity. In
the first method, a nested likelihood ratio test can be used
to select among the linear, 2° polynomial, and 3° polyno-
mial models followed by an Akaike information criterion
(AIC) comparison [22] between the best nested model
and the power model (i.e., the model with the lowest AIC
is selected). In the second method, a completely AIC-
based selection process is performed. Finally, the user is
allowed to remove probe sets where the BMD is greater
than the highest dose. This option was provided to avoid
model extrapolation.
In the output from the BMD analyses, the probe set iden-
tifier is provided with the best overall model together with
selected values for each of the statistical models evaluated.
These include the BMD, the BMDL, the fit p-value from
the likelihood ratio test, the log-likelihood value for the fit
of the model, the AIC, and the direction of the response
(i.e., increased expression or decreased expression). On an
average computer, 10 probe sets can be processed per
minute.
Gene Ontology Analyses
The BMD values from the previous step in the analysis
process are used as input for the GO analyses (Fig. 1D). In
the GO analyses, the probe set identifiers are combined
into unique genes based on their NCBI Entrez Gene iden-
tifiers. When two or more probe sets are associated with a
single gene, the BMDs for the individual probe sets are
averaged to obtain a single value. The Entrez Gene identi-
fiers are then matched to their corresponding biological
process, molecular function, and cellular component GO
categories. The program returns a wide range of summary
values representing the central tendencies and associated
variability of the BMD and BMDL values for the genes
within each category (Table 1).
Example Analysis On Estrogenic Dose-Response in 
Zebrafish (Danio rerio)
To illustrate the features and functionality of BMDEx-
press, microarray data were taken from a study of hepatic
gene expression changes in zebrafish following exposure
to 17 α-ethynylestradiol (EE2) (ArrayExpress Accession
No. E-TABM-105) [23]. In this study, female zebrafish
were exposed to EE2 in the water at nominal concentra-
tions of 0, 15, 40, and 100 ng/L for 24 and 168 h. Gene
expression changes in the liver were then evaluated using
the Affymetrix Zebrafish array to identify potential
genomic biomarkers for endocrine disrupting com-
pounds (natural and synthetic) that are released into the
environment and obtain a better understanding of the
biological effects of these compounds in fish. The data
from the study was downloaded and normalized using
robust multi-array averaging (RMA) with a log2 transfor-
mation [24]. The log2 transformed data for each time
point were imported and analyzed separately using
BMDExpress. The data were pre-filtered using a one-way
ANOVA with a false discovery rate of 5%. A total of 1061
and 864 probe sets showed significant dose-response
behavior at the 24 h and 168 h time-points, respectively.
The data were then fit to linear, 2° polynomial, and power
models and the best model was selected using a likeli-
hood ratio test for the linear and 2° polynomial followed
by an AIC comparison with the power model. The BMD
values from the best model were then used as input for the
GO analysis.
Results from the analysis at the 24 h time point showed
that the most sensitive single gene was tryptophanyl-tRNA
synthetase (Wars) (BMD = 5.74 ng/L) and the most sensi-
tive biological process to EE2 exposure was amino acid
glycosylation (BMD = 10.88 ± 1.80 ng/L) (Table 2). The
four responsive genes in this category all showed similarBMC Genomics 2007, 8:387 http://www.biomedcentral.com/1471-2164/8/387
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dose-response behavior. Based on the BMD values, the
genes relating to amino acid glycosylation and tryptopha-
nyl-tRNA synthetase may be a more sensitive set of
biomarkers than the current single standard biomarker of
vitellogenin [25]. Changes in serum vitellogenin concen-
trations were only significantly altered at the 40 ng/L con-
centration following the 24 h exposure [23]. The
regulation of protein glycosylation by sex steroids has
been well established [26]. For example, the glycosylation
of follicle-stimulating hormone is regulated by estrogens
and androgens and affects its biological activity [27].
Another example is the glycosylation of vitellogenin itself.
Vitellogenin has been shown to be a highly modified pro-
tein [28] and the post-translational changes include glyc-
osylation by hepatocytes [29]. The glycosylation of
vitellogenin provides a source of carbohydrate for the
developing embryo [30] and may play a role in transport,
folding, and uptake of vitellogenin [31]. Other GO cate-
gories that showed low BMD values were cell migration
involved in gastrulation, monocarboxylic acid metabo-
lism, tRNA aminoacylation, nitrogen compound metabo-
lism, and regulation of apoptosis. At the 168 h time point,
the most sensitive single gene was dihydrolipoamide
dehydrogenase (Dldh) (BMD = 5.96 ng/L) and lipid trans-
port was the most sensitive biological process (11.57 ±
2.54 ng/L) (Table 2). In the lipid transport category, one
of the genes was vitellogenin and another was apolipo-
protein A-I. Both genes have been previously shown to be
transcriptionally-regulated by estrogen [25,32]. Other GO
categories that showed relatively low BMD values were
glycolysis, protein-DNA complex formation, and protein
import.
In the original analysis of the data, the investigators used
a linear model to identify genes that were significantly
affected by dose together with a nonparametric stratified
test for trend [23]. Pairwise comparisons between dose-
levels and the control group were also performed. The
investigators summarized these results using Venn dia-
grams showing overlap of genes between doses and used
a GO enrichment analysis at each individual dose show-
ing which processes were affected. The reanalysis of this
dataset using BMDExpress provides several improvements
over the standard analysis performed by the investigators
in the original article. First, the statistical modeling capa-
bilities of BMDExpress utilized the dose-response infor-
Table 1: Output from BMDExpress Characterizing the Dose-dependent Behavior of Each GO Category
Output from GO Analysis Description of Output
GO Level Level in the hierarchy of the GO category
GO Term Name Official name of the GO category
All Genes Total number of genes on the array assigned to the GO category
Genes from BMD Analysis Number of genes from BMD analyses in the GO category
Percentage Percentage of the total number of genes in GO category used in BMD analysis
Gene IDs Entrez Gene identifiers in GO category based on Affymetrix probe set identifiers from BMD analysis
Probe IDs Affymetrix probe set identifiers from BMD analysis
BMD Mean Mean BMD for the genes in GO category
BMD Median Median BMD for the genes in GO category
BMD Minimum Minimum BMD for the genes in GO category
BMD SD Standard deviation of BMD for the genes in GO category
BMD wMean Weighted mean BMD for the genes in GO category (weighted by fit p-value)
BMD wSD Standard deviation of the weighted mean BMD for the genes in GO category (weighted by fit p-value)
BMDL Mean Mean BMDL for the genes in GO category
BMDL Median Median BMDL for the genes in GO category
BMDL Minimum Minimum BMDL for the genes in GO category
BMDL SD Standard deviation of the BMDL for the genes in GO category
BMDL wMean Weighted mean BMDL for the genes in GO category (weighted by fit p-value)
BMDL wSD Standard deviation of the weighted mean BMDL for the genes in GO category (weighted by fit p-value)
5th Percentile Index Nth gene number representing the 5th percentile for all the genes in the category. The value is zero-based 
and a 0.5 value means that it falls between two values
BMD at 5th Percentile BMD at the 5th percentile for all genes in the GO category (including genes with no significant dose 
response)
10th Percentile Index Nth gene number representing the 10th percentile for all the genes in the category. The value is zero-based 
and a 0.5 value means that it falls between two values
BMD at 10th Percentile BMD at the 10th percentile for all genes in the GO category (including genes with no significant dose 
response)
Probes with Adverse Direction Up Number of probe sets in the GO category for which the final change in expression was in the up (i.e., 
increased) direction
Probes with Adverse Direction Down Number of probe sets in the GO category for which the final change in expression was in the down (i.e., 
decreased) directionBMC Genomics 2007, 8:387 http://www.biomedcentral.com/1471-2164/8/387
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mation inherent in the data and identified concentrations
at which the response to the treatment was significantly
changed based on the variability observed in the control
animals. These reference concentrations were not limited
to the specific doses used in the study unlike the analysis
using the linear model and pair-wise comparisons. Sec-
ond, the ability to model the dose-response curves and
calculate associated confidence limits identified a set of
potential biomarkers that were sensitive and robust.
Third, instead of performing a GO enrichment analysis at
each dose level, the analysis by BMDExpress summarized
the data by showing which biological processes were the
most sensitive to environmental estrogens and provided
reference concentrations at which they were affected. In
this manner, the analysis was able to highlight the
changes in amino acid glycosylation that occur at lower
concentrations than the effects on tRNA aminoacylation
and apoptosis.
Conclusion
Despite the numerous software programs for microarray
data analysis, the majority do not provide any statistical
modeling tools for analyzing dose-response studies. In the
past, microarray dose-response studies have been typically
Table 2: Biological process GO categories with the lowest mean BMD in zebrafish exposed to EE2
Biological Process 
GO Categorya












Protein amino acid 
glycosylation




28 3 12.07 0.82 8.24 11.46 0/3
Monocarboxylic acid 
metabolic process
28 3 12.30 5.79 8.15 7.90 5/0
tRNA 
aminoacylation
25 13 12.56 6.62 8.78 5.74 18/0
Nitrogen compound 
catabolic process
11 3 12.57 1.11 8.53 11.75 0/3
Regulation of 
apoptosis
45 3 12.76 2.59 8.59 11.24 2/1
Amino acid and 
derivative metabolic 
process
83 27 12.94 4.82 8.82 5.74 22/12
Amino acid 
metabolic process
72 26 12.99 4.91 8.85 5.74 22/11
Amino acid 
biosynthetic process
18 5 13.05 3.54 8.70 7.90 4/2
Amine metabolic 
process
99 30 13.07 4.63 8.88 5.74 24/14
168 h
Lipid transport 10 3 11.57 2.54 8.60 8.64 1/3
Response to 
external stimulus
41 3 15.99 7.96 8.12 10.75 0/3
Glycolysis 33 6 19.75 10.52 13.14 9.27 2/5
Carbohydrate 
catabolic process
44 7 20.71 9.93 17.79 9.27 3/5
Alcohol metabolic 
process




79 8 23.02 11.28 18.80 9.27 4/5
Protein-DNA 
complex assembly
30 3 23.15 16.13 9.61 12.85 1/2
Monosaccharide 
metabolic process
48 7 23.22 13.28 17.79 9.27 3/5
Cellular protein 
complex assembly
9 3 23.87 15.67 11.39 10.66 1/2
Protein import 17 3 23.87 15.67 11.39 10.66 1/2
aRedundant child GO categories containing the same genes and mean BMD were removed from the list.BMC Genomics 2007, 8:387 http://www.biomedcentral.com/1471-2164/8/387
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analyzed using ANOVA with pair-wise comparisons
between dose groups and the associated control. This type
of analysis only identifies which genes are significantly
altered at the specific doses used in the study. In BMDEx-
press, a statistical model is fit to the data and a dose-level
is identified at which the response to the treatment is sig-
nificantly different than that observed in the control ani-
mals. Using this method, the analysis is not constrained to
the experimental doses and provides better use of the
dose-response information [21]. The software tool then
allows users to summarize the statistical modeling of the
individual genes based on GO categories and characterize
the dose-dependent behavior of specific cellular proc-
esses. These integrated capabilities make BMDExpress a
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